Insights into the molecular determinants involved in Mycobacterium tuberculosis persistence and their therapeutic implications

Virulence. 2021 Dec;12(1):2721-2749. doi: 10.1080/21505594.2021.1990660.

Abstract

The establishment of persistent infections and the reactivation of persistent bacteria to active bacilli are the two hurdles in effective tuberculosis treatment. Mycobacterium tuberculosis, an etiologic tuberculosis agent, adapts to numerous antibiotics and resists the host immune system causing a disease of public health concern. Extensive research has been employed to combat this disease due to its sheer ability to persist in the host system, undetected, waiting for the opportunity to declare itself. Persisters are a bacterial subpopulation that possesses transient tolerance to high doses of antibiotics. There are certain inherent mechanisms that facilitate the persister cell formation in Mycobacterium tuberculosis, some of those had been characterized in the past namely, stringent response, transcriptional regulators, energy production pathways, lipid metabolism, cell wall remodeling enzymes, phosphate metabolism, and proteasome protein degradation. This article reviews the recent advancements made in various in vitro persistence models that assist to unravel the mechanisms involved in the persister cell formation and to hunt for the possible preventive or treatment measures. To tackle the persister population the immunodominant proteins that express specifically at the latent phase of infection can be used for diagnosis to distinguish between the active and latent tuberculosis, as well as to select potential drug or vaccine candidates. In addition, we discuss the genes engaged in the persistence to get more insights into resuscitation and persister cell formation. The in-depth understanding of persistent cells of mycobacteria can certainly unravel novel ways to target the pathogen and tackle its persistence.

Keywords: Mycobacterium tuberculosis; antibiotic tolerance; host immune system; in vitro stress models; persistence; resuscitation; therapeutic approaches; tuberculosis biomarkers.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Drug Tolerance
  • Humans
  • Mycobacterium tuberculosis* / genetics
  • Tuberculosis* / drug therapy
  • Tuberculosis* / microbiology

Substances

  • Anti-Bacterial Agents

Grants and funding

This work was financially supported by a grant to Hemant Joshi from Department of Biotechnology, Government of India [grant number DBT-JRF fellowship DBT/2017/JNU/849].